5338 Camino Playa Norte, San Diego, CA, 92124, USA.
NORMENT Center of Excellence (CoE), Institute of Clinical Medicine, University of Oslo, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway; Department of Medical Genetics, Oslo University Hospital, Oslo, Norway.
Immunol Lett. 2020 Dec;228:45-54. doi: 10.1016/j.imlet.2020.10.001. Epub 2020 Oct 7.
With a rise in the incidence of autoimmune diseases (AiD), health care providers continue to seek out more efficacious treatment approaches for the AiD patient population. Classic serotonergic psychedelics have recently been gaining public and professional interest as novel interventions to a number of mental health afflictions. Psychedelics have also been shown to be able to modulate immune functions, however, while there has been great interest to researching into their psychotherapeutic applications, there has so far been very little exploration into the potential to treat inflammatory and immune-related diseases with these compounds. A handful of studies from a variety of fields suggest that psychedelics do indeed have effects in the body that may attenuate the outcome of AiD. This literature review explores existing evidence that psychedelic compounds may offer a potential novel application in the treatment of pathologies related to autoimmunity. We propose that psychedelics hold the potential to attenuate or even resolve autoimmunity by targeting psychosomatic origins, maladaptive chronic stress responses, inflammatory pathways, immune modulation and enteric microbiome populations.
随着自身免疫性疾病（AiD）发病率的上升，医疗保健提供者继续寻求更有效的治疗方法来治疗 AiD 患者群体。经典的血清素能致幻剂最近作为治疗多种精神疾病的新干预措施引起了公众和专业人士的兴趣。致幻剂也被证明能够调节免疫功能，然而，尽管人们对研究它们的心理治疗应用非常感兴趣，但迄今为止，人们对这些化合物治疗炎症和免疫相关疾病的潜力几乎没有探索。来自不同领域的少数研究表明，致幻剂确实对身体有影响，可能会减轻 AiD 的结果。这篇文献综述探讨了现有的证据，表明致幻化合物可能在治疗与自身免疫相关的病理方面提供一种新的潜在应用。我们提出，致幻剂通过针对身心起源、适应性慢性应激反应、炎症途径、免疫调节和肠道微生物群，有可能减轻甚至解决自身免疫。
